STOKE THERAPEUTICS INC (STOK) Stock Price, Quote, News and Overview
NASDAQ:STOK - Nasdaq - US86150R1077 - Common Stock - Currency: USD
STOK Quote, Performance and Key Statistics
8.33
-0.41 (-4.69%)
The current stock price of STOK is 8.33 USD. In the past month the price decreased by -21.42%. In the past year, price increased by 40.24%.
STOK Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About STOK
Company Profile
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 110 full-time employees. The company went IPO on 2019-06-19. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The firm is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
Company Info
STOKE THERAPEUTICS INC
45 Wiggins Avenue
Bedford MASSACHUSETTS 01730 US
CEO: Edward M. Kaye
Employees: 110
Company Website: https://www.stoketherapeutics.com/
Investor Relations: https://investor.stoketherapeutics.com/
Phone: 17814308200
STOKE THERAPEUTICS INC / STOK FAQ
What is the stock price of STOKE THERAPEUTICS INC today?
The current stock price of STOK is 8.33 USD. The price decreased by -4.69% in the last trading session.
What is the ticker symbol for STOKE THERAPEUTICS INC stock?
The exchange symbol of STOKE THERAPEUTICS INC is STOK and it is listed on the Nasdaq exchange.
On which exchange is STOK stock listed?
STOK stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for STOKE THERAPEUTICS INC stock?
16 analysts have analysed STOK and the average price target is 22.29 USD. This implies a price increase of 167.64% is expected in the next year compared to the current price of 8.33. Check the STOKE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is STOKE THERAPEUTICS INC worth?
STOKE THERAPEUTICS INC (STOK) has a market capitalization of 441.24M USD. This makes STOK a Small Cap stock.
How many employees does STOKE THERAPEUTICS INC have?
STOKE THERAPEUTICS INC (STOK) currently has 110 employees.
What are the support and resistance levels for STOKE THERAPEUTICS INC (STOK) stock?
STOKE THERAPEUTICS INC (STOK) has a resistance level at 10.66. Check the full technical report for a detailed analysis of STOK support and resistance levels.
Is STOKE THERAPEUTICS INC (STOK) expected to grow?
The Revenue of STOKE THERAPEUTICS INC (STOK) is expected to grow by 83.87% in the next year. Check the estimates tab for more information on the STOK EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy STOKE THERAPEUTICS INC (STOK) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of STOK, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of STOK, evaluating the profitability, health, valuation and growth aspects
- STOKE THERAPEUTICS INC (STOK) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- STOKE THERAPEUTICS INC (STOK) Sales and EPS estimates to see what analysts future expectations are.
- STOKE THERAPEUTICS INC (STOK) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- STOKE THERAPEUTICS INC (STOK) Insider and Institutional Ownership to learn about the owners and their transactions.
- STOKE THERAPEUTICS INC (STOK) Stock Chart to make your own analysis
- STOKE THERAPEUTICS INC (STOK) Latest news and press-releases to stay up to date.
Does STOKE THERAPEUTICS INC (STOK) stock pay dividends?
STOK does not pay a dividend.
When does STOKE THERAPEUTICS INC (STOK) report earnings?
STOKE THERAPEUTICS INC (STOK) will report earnings on 2025-03-05, after the market close.
What is the Price/Earnings (PE) ratio of STOKE THERAPEUTICS INC (STOK)?
STOKE THERAPEUTICS INC (STOK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.1).
What is the Short Interest ratio of STOKE THERAPEUTICS INC (STOK) stock?
The outstanding short interest for STOKE THERAPEUTICS INC (STOK) is 17.81% of its float. Check the ownership tab for more information on the STOK short interest.
STOK Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to STOK. When comparing the yearly performance of all stocks, STOK turns out to be only a medium performer in the overall market: it outperformed 68.06% of all stocks.
STOK Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to STOK. No worries on liquidiy or solvency for STOK as it has an excellent financial health rating, but there are worries on the profitability.
STOK Financial Highlights
Over the last trailing twelve months STOK reported a non-GAAP Earnings per Share(EPS) of -2.1. The EPS increased by 13.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.95% | ||
| ROE | -45.43% | ||
| Debt/Equity | 0 |
STOK Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to STOK. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of 13.3% and a revenue growth 83.87% for STOK